-
- Tari King, MD
-
- Tiffany A. Traina, MD
-
- Conleth Murphy, MD
Post by: Tari King, MD; Tiffany A. Traina, MD; Conleth Murphy, MD
Post from: ASCO Breast Cancer Symposium
The potentials and pitfalls of new diagnostic technologies were stunningly reviewed in a lively panel discussion by Dr Alfred O. Berg from EGAPP (Evaluation of Genomic Applications in Practice and Prevention), Dr Robert L. Becker form the FDA, and Dr Daniel F. Hayes from the University of Michigan which provoked considerable audience interest. Discussion centered on the need for evidence-based implementation of emerging molecular tests, and the varied panel of speakers (representing federal, independent evaluation and clinical viewpoints) provided at times contrasting opinions on this topic. All speakers agreed that prospective studies are the ideal way to investigate emerging technologies although well-designed “retrospective-prospective” analyses of good quality trials may be an acceptable alternative.
